HTG Transcriptome Panel - Early Adopter Program
We thank our early adopters for being our customers, advocates and helping us shape the future of gene expression profiling with the HTG Transcriptome Panel. We are grateful for your support and realize that you are the essential part of what powers innovation and breakthroughs.
The University of Texas
MD Anderson Cancer Center
Saint John’s
Cancer Institute
Duke University
Medical Center
Fundación Instituto
Valenciano de Oncologia
Tyrolpath Obrist
Brunhuber GmbH
University Hospital Essen
Johannes Wesling Hospital Minden
Featured Publication
Cross-platform comparison of immune-related gene expression to assess intra tumor immune response following cancer immunotherapy
READ PUBLICATION
News & Events
HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , July 23, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that, on July 13th and July 22nd, 2021 the Compensation Committee of the HTG Board of Directors granted
- Category:
- Press Releases
HTG Forms New Drug Discovery Business Unit
New unit to focus on development of drug candidates through use of HTG Transcriptome Panel TUCSON, Ariz. , July 20, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the creation of
- Category:
- Press Releases
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
TUCSON, Ariz. , June 22, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed
- Category:
- Press Releases
HTG Completes Product Design Lock for its Planned Transcriptome Panel and Announces the Signing of the Three Early Adopter Program Collaboration Agreements
TUCSON, Ariz. , June 14, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed product design lock for the HTG Transcriptome Panel and announced three Early Adopter
- Category:
- Press Releases
HTG EdgeSeq Technology Highlighted in Several Posters Being Presented at the American Society of Clinical Oncology 2021 Virtual Conference
TUCSON, Ariz. , May 24, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG EdgeSeq technology is highlighted in several posters being presented at the American Society of
- Category:
- Press Releases
HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update
Call scheduled for today, May 13, at 4:30 pm ET TUCSON, Ariz. , May 13, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31,
- Category:
- Press Releases
Careers at HTG
At HTG Molecular Diagnostics, Inc., we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.
Featured Positions
New Careers
Resources
Find product information, specifications and gene lists here.
Publications
Read white papers or journal publications and view other scientific content.
Support
Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels.
Page last updated July 07, 2021
Ready to get started?
HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.